ipilimumab,nivolumab
bms
[]
#gi23 presents 3 year follow up data for cm649. previous benefits seen are sustained with nivo chemo. higher pdl1 cps correlated with better orr. massive separation in km curve seen in msi-high population (not pictured) 
Fellow @PennCancer. @NIH_LRP.  @PC3Innovation. MSCE Student. GI Cancers. Former @UTSWIMchief. Lucas’ dad forever. Views own. ASCO FCOI https://t.co/rmHB23k0Ph